Dr. Al-Ahmadi: bladder cancer subtypes vary in biology and outcomes; accurate classification and molecular profiling are key to guiding treatment. Dr. Jain: Neoadjuvant ADCs in MIBC show high pCR rates; EVP outperforms chemo but has toxicity; future trials aim to refine use and avoid overtreatment. Dr. Johnson: ctDNA in urothelial cancer guides periop care: clearance predicts outcomes; trials show ICI benefit, with ctDNA status aiding risk stratification and treatment. Dr. Brown: Post EV+pembro UC: many need 2L therapy; platinum, HER2, FGFR inhibitors show activity; novel ADCs and vaccines show early promise. Dr. Vaena: ADCs targeting B7H3, HER2, TROP2 show promise but have toxicity risks; ctDNA and genomics may guide safer, personalized treatment strategies. Dr. Siefker-Radtke: Variant histology in UC affects outcomes; chemo helps small cell types, IO shows promise; need better trials and HER2-targeted ADC strategies. Panel: Even minor variant histology matters; ctDNA may guide MRD but needs data; EV+pembro favored for lower toxicity; de-escalation trials needed.